We bring you the latest news from the healthcare about the health care in the United Kingdom.

zaterdag 22 september 2018

Food Standards Agency: FSA Board meeting: 19 September 2018

FSA Board meeting: 19 September 2018
Today's open Board meeting is now live.
Read more

Summary of discussions at FSA Board meeting 19 September 2018
At its quarterly meeting today, the Food Standards Agency Board discussions included: further elements of the regulatory reform programme (Regulating Our Future or ROF); progress on food and antimicrobial resistance (AMR), including in the dairy sector; its annual report on animal welfare; and changes to its governance arrangements in consequence of EU Exit.
Read more

FSA September Board meeting now available online
The latest open Board meeting is now available as a video-on-demand.
Read more

International Journal of Care Coordination Vol. 21, No. 3, September 1, 2018 is now available online

Table of Contents Alert
International Journal of Care Coordination- Volume: 21, Number: 3 (September 2018)

Special Issue: Realist research in health services research and care coordination

Special Issue: Realist research in health services research and care coordination and
Discussion & Opinion Paper
The need for theory-based evaluation of care coordination initiatives: Considerations from the 2017 International Conference on Realist Research, Evaluation and Synthesis , , , and
Developing programme theories as part of a realist evaluation of a healthcare quality improvement programme
Reviews: Systematic Reviews & Meta-analyses
Mobile health and the performance of maternal health care workers in low- and middle-income countries: A realist review , , , , and
How do integrated care programmes work for patients with cardiovascular disease, chronic obstructive pulmonary disease, depression, diabetes and multi-morbidity? A rapid realist review , , and
Research Paper
A system-wide transformation towards integrated care in the Basque Country: A realist evaluation , , and

This message was sent to dezorgsector.uk@gmail.com. Unsubscribe from this alert or manage your alerts from SAGE Journals.

SAGE Publishing * 2455 Teller Road * Thousand Oaks, CA 91320 * U.S.A.

Privacy Policy

© 2018 SAGE Journals. All Rights Reserved.

The Lancet: [Comment] Juvenile Huntington's disease: left behind?

[Comment] Juvenile Huntington's disease: left behind?
Most movement disorders specialists will care for only a handful of children with juvenile Huntington's disease (onset at age 20 years or younger) during a lifetime of clinical practice. Therefore, the retrospective study of 36 children and adolescents with juvenile Huntington's disease reported by Caterina Fusilli and colleagues1 in The Lancet Neurology is extraordinary because this sample size, which is large considering the low prevalence rate, provides a rich opportunity to examine key features of juvenile Huntington's disease.
Read more

[Corrections] Corrections
Al-Shahi Salman R, Frantzias J, Lee RJ, et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurol 2018; 17: 885–94—The affiliation of Department of Neurology, University of Erlangen-Nuremberg, Erlangen, Germany has been added for authors Dimitre Staykov and Bastian Volbers. This correction has been made to the online version as of Sept 19, 2018.
Read more

[Review] Nutrition and prevention of cognitive impairment
Nutrition is an important lifestyle factor that can modify the risk of future cognitive impairment and dementia. Some, but not conclusive, evidence (mostly from observational studies and infrequently from clinical trials) exists of a protective association between certain nutrients (eg, folate, flavonoids, vitamin D, and certain lipids) or food groups (eg, seafood, vegetables, and fruits, and potentially moderate alcohol and caffeine consumption) and cognitive outcomes in older people. For some nutrients and food groups, protection might be greater in individuals with either deficiencies in certain nutrients or a genetic predisposition to cognitive impairment.
Read more

[Review] Comorbidities, treatment, and pathophysiology in restless legs syndrome
Restless legs syndrome, also known as Willis-Ekbom disease, is a common neurological condition whose manifestation is affected by complex environmental and genetic interactions. Restless legs syndrome can occur on its own, mostly at a young age, or with comorbidities such as cardiovascular disease, diabetes, and arterial hypertension, making it a difficult condition to properly diagnose. However, the concept of restless legs syndrome as being two entities, primary or secondary to another condition, has been challenged with genetic data providing further insight into the pathophysiology of the condition.
Read more

[In Context] The science of today is all about tomorrow
Perhaps some remember science lessons at school as intimidating, or even boring, associated with something out of reach: esoteric or mysterious. Making science relevant, meaningful, or accessible to the non-scientist is important if you want to engage "the ordinary visitor", a term used by the previous director of what is now known as the Science Museum (London, UK), Colonel Sir Henry Lyons. So, in 1931, he opened a Children's Gallery to demonstrate scientific principles in a fun format, in today's parlance—hands-on and interactive.
Read more

The Lancet: [Correspondence] Partnerships with the alcohol industry: opportunities and risks

[Correspondence] Partnerships with the alcohol industry: opportunities and risks
The continuing health harms of alcohol1 require action not inaction.2 A range of effective policy interventions are available, and Public Health England (PHE) has been prominent in bringing all of these to the attention of policy makers.3 In The Lancet, Mark Petticrew and colleagues4 discuss PHE's partnership with the charity Drinkaware and suggest that such collaborations could be at the expense of public health.
Read more

[Department of Error] Department of Error
Kruk ME, Gage AD, Joseph NT, Danaei G, García-Saisó S, Salomon JA. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries Lancet 2018; https://doi.org/10.1016/S0140-6736(18)31668-4—In figure 2 of this Article (published Online First on Sept 5, 2018), the y axis should read "deaths in 100 000s". The affiliation for Prof Salomon should read "Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, CA, USA".
Read more

[Comment] 10 years after the Commission on Social Determinants of Health: social injustice is still killing on a grand scale
In 2008, WHO launched the final report of the Commission on Social Determinants of Health (CSDH) that concluded "social injustice is killing people on a grand scale".1 A decade later, how should we judge the CSDH's impact? A Google search for the CSDH yields 156 000 results and the accompanying Lancet paper has had 932 citations.2 The CSDH led to two World Health Assembly resolutions and more than 100 countries adopted the Rio Political Declaration on Social Determinants of Health in 2011.3 The CSDH's report has become a foundational text for how crucial social determinants are to health and health equity.
Read more

[Articles] Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
The addition of ustekinumab to standard-of-care treatment resulted in better efficacy in clinical and laboratory parameters than placebo in the treatment of active systemic lupus erythematosus and had a safety profile consistent with ustekinumab therapy in other diseases. The results of this study support further development of ustekinumab as a novel treatment in systemic lupus erythematosus.
Read more

[Comment] Ustekinumab: a promising new drug for SLE?
In The Lancet, Ronald van Vollenhoven and colleagues1 report a positive multicentre double-blind phase 2 randomised, placebo-controlled trial with ustekinumab, an anti-interleukin-12/23 (IL-12/23) monoclonal antibody, in 102 patients aged 18–75 years with active systemic lupus erythematosus (93 women and nine men). The design of the study is common for trials of biotherapies in patients with systemic lupus erythematosus: ustekinumab was assessed as add-on treatment to standard-of-care therapy in patients with active disease, excluding severe cases with active glomerulonephritis, systemic vasculitis, or CNS involvement.
Read more